IMDELLTRA (tarlatamab-dlle) for injection
IMDELLTRA (tarlatamab-dlle) – Lung Cancer Therapy in India
It is indicated for treating adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease progressed after or during platinum-based chemotherapy, functioning as a bispecific T-cell engager to target DLL3-expressing cancer cells. It’s approved under accelerated FDA approval, with ongoing trials to confirm clinical benefit.
| Brand Name: | IMDELLTRA |
| Generic Name: | tarlatamab-dlle for injection |
| Strength: | • For injection: 1 mg of lyophilized powder in a single-dose vial for reconstitution and further dilution. • For injection: 10 mg of lyophilized powder in a single-dose vial for reconstitution and further dilution. |
| Manufacturer: | Amgen Inc |
| Approved By: | EMA, USFDA |
Source Details: Patient Information.
IMDELLTRA must always be used under the supervision of a Registered Medical Practitioner (RMP).
Access IMDELLTRA for Lung Cancer on a Named Patient Import Basis
IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to IMDELLTRA (tarlatamab-dlle) For Injection for personal use. To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).
For any queries, including information regarding the cost of the pharmaceutical product in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774.
Note: All access is provided strictly on a Named Patient Import Basis and for personal use only, in accordance with Indian regulatory guidelines.
Contact Info
CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
EMAIL ID:
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer. It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3. The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.
The drug, tarlatamab, is now approved to treat adults whose extensive-stage small cell lung cancer has progressed on or after treatment with platinum-based chemotherapy.
Small cell lung cancer (SCLC) is less common than non-small cell lung cancer, but it is more aggressive, rapidly spreading to other parts of the body. The five-year survival rate for extensive-stage SCLC is 3%, according to the American Cancer Society. Second-line treatments for this advanced cancer include more chemotherapy as well as a class of immunotherapies called checkpoint inhibitors, which block proteins that cancers use to evade detection by the immune system.
Contact IPN – IMDELLTRA Access in India
For inquiries regarding availability, import process, or cost of IMDELLTRA (tarlatamab-dlle):
India Pharma Network (IPN) : Headquartered in New Delhi, with branch offices in Delhi, Gurugram, Mumbai, Bangalore, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur and Lucknow, IPN supports medicine imports across India on a Named Patient Import Basis and for personal use only. Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774. Email: info@indianpharmanetwork.co.in
NEWS/UPDATES
- FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer.
- FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER.
- FDA Approves Tarlatamab for Small Cell Lung Cancer.
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based ChemotherapyA review of FDA approved.drugs and their formulations for the treatment of breast cancer.
Compliance & Disclaimer
India Pharma Network acts solely as a facilitator for IMDELLTRA (tarlatamab-dlle) access. IPN does not manufacture, sell, or promote medicines and does not provide medical advice. All imports are:
- Strictly on a Named Patient Import Basis
- Exclusively for personal use
- Not for resale, distribution, or commercial sale
- Subject to applicable Indian laws and regulatory approvals
The prescribing physician remains solely responsible for dosage, therapy, and clinical decisions.
Why IPN?
India Pharma Network (IPN) helps patients, doctors, and hospitals import medicines to India that are not readily available in the domestic market. With over 10 years of experience, IPN provides end-to-end facilitation for accessing specialized, orphan, and life-saving medicines, strictly in compliance with Indian regulations.
Why Choose India Pharma Network in India?
- 10+ years of experience in importing specialty medicines in India
- Expertise in lung cancer and oncology therapies
- Nationwide presence with offices in Delhi, Kolkata, and Mumbai
- Strict adherence to Named Patient Basis regulations
- Transparent, patient-focused service
FAQs
Who Can Access IMDELLTRA (tarlatamab-dlle) for injection in India?
IPN facilitates access to IMDELLTRA for:
- Patients prescribed IMDELLTRA by their oncologist
- Doctors and treating physicians seeking access for patients
- Hospitals and oncology centers managing lung cancer therapies
All imports are patient-specific and cannot be used for commercial purposes.
How to Import IMDELLTRA (tarlatamab-dlle) for injection to India
- Valid Prescription: Must be issued by a Registered Medical Practitioner (RMP)
- Form 12A Application: Required by Indian regulatory authorities for medicine import
- Supporting Medical Documentation: As applicable for approval
India Pharma Network (IPN) assists with:
- Preparing and submitting documentation
- Liaising with regulatory authorities
- Coordinating import and delivery
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in